Abstract
Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have